文献速递临床微生物质量管理与危急值

奥马环素对肠杆菌目VITEK 2药敏试验的多中心临床性能评估

Multicenter Clinical Performance Evaluation of Omadacycline Susceptibility Testing of Enterobacterales on VITEK 2 Systems.
PubMed 文献 · J Clin Microbiol · 2023-05-10

在5个美国站点评估奥马环素VITEK 2与VITEK 2 Compact对858株肠杆菌目的药敏性能,以CLSI微量肉汤稀释法为参考。按FDA标准(仅肺炎克雷伯菌和阴沟肠杆菌)EA为97.9%、CA为94.3%、VME为2%、无ME;按ISO标准(全部肠杆菌目)纠错后EA为98.1%、CA为96.9%、无ME或VME。VITEK 2试验满足ISO和FDA的≥95%重现性和≥95%质控要求,并于2022年6月获FDA 510(k)许可。

要点

  • VITEK 2奥马环素药敏试验与BMD参考方法高度一致,满足FDA和ISO性能标准。
  • FDA标准下VME为2%(1/51),无ME;ISO标准下无ME或VME。
  • 该试验已于2022年6月获FDA 510(k)许可,用于特定感染治疗中的肠杆菌目检测。

核心结论

  • VITEK 2奥马环素药敏试验对肠杆菌目表现良好,满足FDA和ISO性能标准,可作为BMD参考方法的替代。

研究设计与样本

  • 在美国5个站点(4个外部、1个内部)开展多中心评估,以CLSI微量肉汤稀释法为参考方法。
  • 共测试858株肠杆菌目,比较VITEK 2 AST-GN卡奥马环素结果与参考方法。

主要发现

  • 按FDA标准(仅肺炎克雷伯菌和阴沟肠杆菌)EA为97.9%(410/419)、CA为94.3%(395/419)、VME为2%(1/51)、无ME。
  • 按ISO标准(全部肠杆菌目)纠错后EA为98.1%(842/858)、CA为96.9%(831/858)、无ME或VME。
  • VITEK 2试验满足ISO和FDA的≥95%重现性和≥95%质控结果在可接受范围的要求。

关键数值与推荐

  • FDA标准分析仅纳入肺炎克雷伯菌和阴沟肠杆菌,EA 97.9%、CA 94.3%、VME 2%、无ME。
  • ISO标准分析纳入全部肠杆菌目,纠错后EA 98.1%、CA 96.9%、无ME或VME。
  • 性能要求为≥95%重现性和≥95%质控结果在可接受范围。

临床怎么用

  • VITEK 2奥马环素药敏试验可用于测定肠杆菌目奥马环素MIC,替代BMD参考方法。
  • 2022年6月获FDA 510(k)许可(K213931),用于治疗由阴沟肠杆菌和肺炎克雷伯菌引起的急性细菌性皮肤及皮肤结构感染,以及由肺炎克雷伯菌引起的社区获得性细菌性肺炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the first performance evaluation results for omadacycline on the VITEK 2 and VITEK 2 Compact Systems (bioMérieux, Inc.). The trial was conducted at four external sites and one internal site. All sites were in the United States, geographically dispersed as follows: Indianapolis, IN; Schaumburg, IL; Wilsonville, OR; Cleveland, OH; and Hazelwood, MO. In this multisite study, omadacycline was tested against 858 Enterobacterales on the VITEK 2 antimicrobial susceptibility test (AST) Gram-negative (GN) card, and the results were compared to the Clinical and Laboratory Standards Institute broth microdilution (BMD) reference method. The results were analyzed and are presented as essential agreement (EA), category agreement (CA), minor error (mE) rates, major error (ME) rates, and very major error (VME) rates following the US Food and Drug Administration (FDA) and International Standards Organization (ISO) performance criteria requirements. Omadacycline has susceptibility testing interpretive criteria (breakpoints) established by the FDA only; nevertheless, the analysis was also performed using the ISO acceptance criteria to satisfy the registration needs of countries outside the United States. The analysis following FDA criteria (including only Klebsiella pneumoniae and Enterobacter cloacae) showed the following performance: EA = 97.9% (410/419), CA = 94.3% (395/419), VME = 2% (1/51), with no ME present. The performance following ISO criteria (including all Enterobacterales tested) after error resolutions was EA = 98.1% (842/858) and CA = 96.9% (831/858). No ME or VME were observed. The VITEK 2 test met the ISO and FDA criteria of ≥ 95% reproducibility, and ≥ 95% quality control (QC) results within acceptable ranges for QC organisms. In June 2022, the omadacycline VITEK 2 test received FDA 510(k) clearance (K213931) FDA as a diagnostic device to be used in the treatment of acute bacterial skin and skin-structure infections caused by E. cloacae and K. pneumoniae, and for treatment of community-acquired bacterial pneumonia caused by K. pneumoniae. The new VITEK 2 AST-GN omadacycline test provides an alternative to the BMD reference method testing and increases the range of automated diagnostic tools available for determining omadacycline MICs in Enterobacterales.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Csiki-Fejer E, Traczewski M, Procop GW, et al. Multicenter Clinical Performance Evaluation of Omadacycline Susceptibility Testing of Enterobacterales on VITEK 2 Systems. J Clin Microbiol. 2023. PMID: 37162363. doi:10.1128/jcm.00174-23

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。